Maravai Lifesciences Holdings Inc (MRVI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Maravai Lifesciences Holdings Inc stock $6.27, price $7.52, that is 16.6% below the price, quality 33 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $1.72 – $60.62 · fair‑value band $5.00 – $7.53 · the $7.52 price screens above the $6.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Maravai Lifesciences Holdings in your weekly email
Every Wednesday you see whether Maravai Lifesciences Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Show moreShow less
It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.
The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.
The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products.
It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Stock analysis
Maravai Lifesciences Holdings Inc (MRVI) currently trades at $7.52, while our model-based Fair Value estimate is $6.27, 17% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 81/100, which puts the data coverage at low.
Scenario range: $5.00 (bear) to $7.53 (bull), the price of $7.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Maravai Lifesciences Holdings Inc reported revenue of $186M in FY2025 versus $799M in FY2021, a compound −30.6%/yr. Reported net income was −$131M in FY2025.
Key figures
Market cap $2.9B Mid · P/S ratio 13.7 · EPS (TTM) $−0.5300 · Net margin −37.1% · Return on equity −33.1% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin −29.4% · Revenue (TTM) $209M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 16% below its 52-week high and 166% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −17%, MRVI screens richer than that median.
Fair Value models
Bear$5.00Fair Value $6.27Bull$7.53
Price $7.52 · Downside -16.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $254,000 and none bought.
SaleKurt OreshackGeneral Counsel50,000 shares at $5.08$254,000Jun 10, 202610b5-1 plan
BuyGregory T LucierDirector100,000 shares at $3.69$368,544Dec 8, 2025
BuyBernd BrustChief Executive Officer, Director2× since Nov 11, 2025: 466,771 shares, avg. $3.24$1.5MNov 13, 2025
Plus 20 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−40.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
42.2% (2020) → −3.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
AI conclusion: The new China patent strengthens CleanCap intellectual property protection, yet persistent negative cash flows and margins reveal a weak durable advantage in the competitive biotech sector.
Main risk: Slower recovery in broader biotech research spending would delay conversion of cost discipline into lasting growth and pressure margins.
Maravai’s TriLink subsidiary secured a second China patent in late September that protects the CleanCap molecules themselves along with their use in RNA drugs. This strengthens the core intellectual property moat in a business still transitioning away from COVID-related revenue. At the same time the company relies on a rebound in broader biotech research spending to turn recent cost discipline into lasting growth. Will the new patent protection generate licensing income fast enough to offset slower recovery in customer programs?
Compare Maravai Lifesciences Holdings Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−16.6% · Above median
Profitability
Return on assets−17.0% · Below median
Net margin (12 months)−37.1% · Bottom 25%
Operating margin (12 months)−29.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)8.5% · Above median
Balance sheet
Debt / equity1.35× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B13.46× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Maravai Lifesciences Holdings Inc (MRVI) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $6.27 versus a price of $7.52, about 17% lower (overvalued).
What is the fair value of MRVI?
Our model-based fair value for Maravai Lifesciences Holdings Inc is $6.27 (as of Nov 8, 2026), built from audited fundamentals. The current price: $7.52.
What is the quality score of MRVI?
Maravai Lifesciences Holdings Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Maravai Lifesciences Holdings Inc (MRVI)?
Our model-based price target is the fair value of $6.27 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $5.00, optimistic scenario $7.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Maravai Lifesciences Holdings Inc stock forecast for 2026?
Our models put fair value at $6.27, about 17% lower versus a price of $7.52 (overvalued). Cautious scenario $5.00, optimistic scenario $7.53. The calculation is refreshed regularly with new filings.
What is the revenue of Maravai Lifesciences Holdings Inc (MRVI)?
Maravai Lifesciences Holdings Inc reported trailing-twelve-month revenue of about $209M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Maravai Lifesciences Holdings Inc (MRVI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Maravai Lifesciences Holdings Inc it is $6.27 per share (as of Nov 8, 2026), against a price of $7.52. It is the blended result of 1 valuation models in 1 family (Multiples).
Is Maravai Lifesciences Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, MRVI trades above its calculated fair value: price $7.52, fair value $6.27, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MRVI?
No. The price is what the market pays today ($7.52); the fair value is what the company's own numbers justify ($6.27). For Maravai Lifesciences Holdings Inc the two are $1.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is Maravai Lifesciences Holdings Inc worth?
The market values Maravai Lifesciences Holdings Inc at about $2.9B (market capitalisation, as of Nov 8, 2026). Per share that is $7.52; our models calculate a fair value of $6.27 per share.
What do the bullish and bearish scenarios say about MRVI?
Our models span a range for Maravai Lifesciences Holdings Inc: cautious scenario $5.00, base $6.27, optimistic $7.53 per share (as of Nov 8, 2026, price $7.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Maravai Lifesciences Holdings Inc (MRVI)?
Balance-sheet figures for Maravai Lifesciences Holdings Inc (as of Nov 8, 2026): return on equity −33.1%, debt of 1.35 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is MRVI from its 52-week high?
Maravai Lifesciences Holdings Inc trades at $7.52, about 16% below its 52-week high of $9.00 and 166% above the low of $2.83 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $6.27 is for.
Which stocks are comparable to Maravai Lifesciences Holdings Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Maravai Lifesciences Holdings Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $7.52, calculated fair value $6.27 (−17%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MRVI calculated?
We run Maravai Lifesciences Holdings Inc through 1 models from 1 family: Multiples. Every model gets the same audited fundamentals; the fair value of $6.27 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Maravai Lifesciences Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Maravai Lifesciences Holdings Inc (MRVI)?
The closing price on Nov 6, 2026 was $7.52. Our model-based fair value is $6.27, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Maravai Lifesciences Holdings Inc right now?
Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Maravai Lifesciences Holdings Inc
How large is the market capitalisation of Maravai Lifesciences Holdings Inc (MRVI)?
The market capitalisation of Maravai Lifesciences Holdings Inc is $2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Maravai Lifesciences Holdings Inc (MRVI)?
The price-to-sales ratio of Maravai Lifesciences Holdings Inc is 13.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Maravai Lifesciences Holdings Inc (MRVI)?
Earnings per share at Maravai Lifesciences Holdings Inc are $−0.5300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Maravai Lifesciences Holdings Inc (MRVI)?
The net margin of Maravai Lifesciences Holdings Inc is −37.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Maravai Lifesciences Holdings Inc (MRVI)?
The return on equity (ROE) of Maravai Lifesciences Holdings Inc is −33.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Maravai Lifesciences Holdings Inc (MRVI)?
On an EBIT basis the return on assets of Maravai Lifesciences Holdings Inc is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Maravai Lifesciences Holdings Inc (MRVI)?
The operating margin of Maravai Lifesciences Holdings Inc is −29.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Maravai Lifesciences Holdings Inc (MRVI)?
Revenue at Maravai Lifesciences Holdings Inc is growing +8.5% versus a year earlier (3y avg −40.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Maravai Lifesciences Holdings Inc (MRVI)?
Earnings per share at Maravai Lifesciences Holdings Inc are growing −32.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Maravai Lifesciences Holdings Inc (MRVI) generate?
The free cash flow of Maravai Lifesciences Holdings Inc is −$70.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Maravai Lifesciences Holdings Inc (MRVI) hold?
Maravai Lifesciences Holdings Inc holds more cash than debt, $181M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Maravai Lifesciences Holdings Inc in the live analysis
One click puts Maravai Lifesciences Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
